Vanda Pharmaceuticals | VNDA - Cash And Equivalent


Vanda Pharmaceuticals reported $84.85M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 956.47M 105.02M Jun/2026
Agios Pharmaceuticals USD 99.65M 13.95M Jun/2026
Akebia Therapeutics USD 155.55M 7.1M Jun/2026
Alnylam Pharmaceuticals USD 1.71B 2.46M Jun/2026
Anika Therapeutics USD 38.41M 2.61M Jun/2026
Arrowhead Research USD 19.68M 127.85M Jun/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Eli Lilly USD 8.95B 3.67B Jun/2026
Enanta Pharmaceuticals USD 37.44M 5.14M Dec/2025
Halozyme Therapeutics USD 163.14M 146.61M Jun/2026
Heron Therapeutics USD 20.72M 5.4M Jun/2026
Insmed USD 544.76M 37.42M Jun/2026
J&J USD 20.42B 1.27B Jun/2026
Lexicon Pharmaceuticals USD 38.09M 3.76M Mar/2026
Ligand Pharmaceuticals USD 1.01B 891.62M Jun/2026
Merck USD 6.85B 1.52B Jun/2026
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Moderna USD 1.72B 185M Jun/2026
Novartis USD 6.88B 2.68B Mar/2026
Pfizer USD 976M 727M Jun/2026
PTC Therapeutics USD 1.05B 215.9M Jun/2026
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sanofi EUR 6.35B 806M Jun/2026
Takeda JPY 460.98B 134.07B Jun/2026
Teva Pharmaceutical Industries USD 3.74B 185M Mar/2026
Ultragenyx Pharmaceutical USD 125M 50M Jun/2026
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025
Veracyte USD 299.52M 36.38M Jun/2026